The influence of CYP2C19*2 and CYP3A5*3 variants on the development of depression and effectiveness of therapy: A preliminary study
Open Access
- 1 October 2021
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 142, 112055
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- CYP3A5 Functions as a Tumor Suppressor in Hepatocellular Carcinoma by Regulating mTORC2/Akt SignalingCancer Research, 2015
- Involvement of Cytochrome P450 in Reactive Oxygen Species Formation and Cancer2015
- Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control studyBreast Cancer Research, 2014
- Genetic differences in cytochrome P450 enzymes and antidepressant treatment responseJournal of Psychopharmacology, 2013
- Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010PLOS Medicine, 2013
- Functional Polymorphisms in the CYP2C19 Gene Contribute to Digestive System Cancer Risk: Evidence from 11,042 SubjectsPLOS ONE, 2013
- Association between CYP2C19 polymorphism and depressive symptomsAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010
- Molecular epidemiology of major depressive disorderEnvironmental Health and Preventive Medicine, 2009
- CYP2C19*17 is associated with decreased breast cancer riskBreast Cancer Research and Treatment, 2008
- Complex reactions catalyzed by cytochrome P450 enzymesBiochimica et Biophysica Acta (BBA) - General Subjects, 2007